N-[(2R)-1-(cyanomethylamino)-3-[[2-(difluoromethoxy)phenyl]methylsulfonyl]-1-oxopropan-2-yl]-4-fluorobenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(2R)-1-(cyanomethylamino)-3-[[2-(difluoromethoxy)phenyl]methylsulfonyl]-1-oxopropan-2-yl]-4-fluorobenzamide
• 化学式: C₂₀H₁₈F₃N₃O₅S
• 分子量: 469.4
• InChiKey: KXSHSEVBLHLNIO-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  32
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• Novel compounds and compositions as cathepsin S inhititors
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：US20040014796A1

  公开（公告）日：2004-01-22

  The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及新型选择性卡痕蛋白S抑制剂，其药学上可接受的盐和N-氧化物，它们作为治疗剂的用途以及它们的制备方法。
• Sphingosine-1-phosphate (S1P) receptor agonists for use in the treatment of demyelinating diseases
  申请人：Novartis AG

  公开号：EP2251007A2

  公开（公告）日：2010-11-17

  Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.

  所公开的是包含至少一种S1P受体激动剂的药物组合，以及一种治疗脱髓鞘疾病（如多发性硬化症或与之相关的疾病或吉兰-巴雷综合征）的方法，该方法包括共同给药，例如同时或依次给药治疗有效量的a)S1P受体激动剂，和b)至少一种被证明对脱髓鞘疾病的至少一种症状具有临床活性的联合试剂。
• Sphingosine-1-phosphate receptor agonists for use in the treatment of optic neuritis
  申请人：Novartis AG

  公开号：EP2255798A2

  公开（公告）日：2010-12-01

  Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1 P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.

  所公开的是包含至少一种S1P受体激动剂的药物组合，以及一种治疗脱髓鞘疾病（如多发性硬化症或与之相关的疾病或吉兰-巴雷综合征）的方法，该方法包括共同给药，例如同时或依次给药治疗有效量的a) S1 P受体激动剂，和b) 至少一种被证明对脱髓鞘疾病的至少一种症状具有临床活性的联合试剂。
• PAEDIATRIC COMPOSITIONS FOR TREATING MULTIPLE SCLEROSIS
  申请人：Novartis AG

  公开号：EP3011958A1

  公开（公告）日：2016-04-27

  The present invention relates to pharmaceutical compositions comprising a 2-amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol compound or a pharmaceutically acceptable salt thereof, and to the use thereof for treating, preventing or delaying the progression of multiple sclerosis in a paediatric patient or a patient suffering from a specific condition.

  本发明涉及包含 2-氨基-2-[2-(4-C2-20-烷基-苯基)乙基]丙烷-1,3-二醇化合物或其药学上可接受的盐的药物组合物，并涉及其用于治疗、预防或延缓儿科患者或特定病症患者的多发性硬化症的进展。
• Organic compounds
  申请人：Foster Ann Carolyn

  公开号：US20060046979A1

  公开（公告）日：2006-03-02

  Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.

  所公开的是包含至少一种S1P受体激动剂的药物组合，以及一种治疗脱髓鞘疾病（如多发性硬化症或与之相关的疾病或吉兰-巴雷综合征）的方法，该方法包括共同给药，例如同时或依次给药治疗有效量的a)S1P受体激动剂，和b)至少一种被证明对脱髓鞘疾病的至少一种症状具有临床活性的联合试剂。